Connect with us

Health

NHS Rolls Out New Anti-Smoking Drug to Boost Quit Rates Amid Push for a Smoke-Free UK

Published

on

England’s National Health Service (NHS) has reintroduced an enhanced anti-smoking drug, Varenicline, aimed at increasing success rates for those seeking to quit smoking. Marketed as a prescription-only treatment, Varenicline offers an effective alternative to nicotine-replacement therapies like gum or patches and is comparable to vaping in its ability to curb smoking habits, according to NHS England.

The drug, taken daily, is reported to both reduce nicotine cravings and block the pleasurable effects of smoking on the brain. By minimizing withdrawal symptoms such as irritability and insomnia, Varenicline is seen as a promising tool in the NHS’s suite of smoking cessation options. When paired with counseling or other psychotherapeutic support, NHS data suggests that around 25% of users successfully quit smoking for six months or longer.

The reintroduction of Varenicline is expected to have a substantial public health impact. Research from University College London (UCL) indicates that the drug could assist more than 85,000 people in quitting smoking each year and could prevent up to 9,500 smoking-related deaths over the next five years.

“Prevention is better than cure,” said Wes Streeting, the UK’s Health and Social Care Secretary, in a statement regarding the drug’s rollout. “The availability of this pill can save the NHS millions, speed up appointment availability for other patients, and save lives.”

Previously available under the brand name Champix, Varenicline was withdrawn from NHS prescriptions in 2021 due to the detection of an impurity. However, the newly launched version has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), confirming its safety and efficacy.

See also  Switching from Gas to Electric Stoves May Help Reduce Asthma Symptoms, Study Finds

NHS Chief Executive Amanda Pritchard emphasized Varenicline’s role in the NHS’s preventive healthcare focus during a speech at the NHS Providers annual conference. “This simple daily pill could be a game-changer for those looking to quit smoking and marks another significant step toward prevention,” she said. “Smoking remains one of the biggest public health issues, impacting the lungs, heart, blood, and brain, and increasing the risk of serious conditions such as cancer and diabetes.”

The launch of Varenicline aligns with the UK’s broader anti-smoking goals, which include a proposed bill to prevent individuals born after January 1, 2009, from legally purchasing cigarettes. Currently, about 12% of adults in the UK smoke, a figure that correlates with over 400,000 smoking-related hospital admissions in England from 2022 to 2023.

The NHS already offers various smoking cessation options, including nicotine replacement therapies and the antidepressant Bupropion (Zyban), which has been shown to reduce cravings. While vaping is also commonly used, it remains unavailable through NHS prescriptions. The National Institute for Health and Care Excellence (NICE) instead recommends licensed stop-smoking medications like Varenicline.

Professor Nick Hopkinson, a respiratory medicine expert at Imperial College London, described Varenicline as “the most effective smoking cessation medication” and emphasized that pairing it with counseling support can improve quit success rates. Dr. Sarah Jackson, principal research fellow at the UCL Tobacco and Alcohol Research Group, added that Varenicline’s availability “can help more people avoid years of ill health and early death.”

With the NHS spending £2.5 billion annually on smoking-related health issues, the reintroduction of Varenicline is viewed as a cost-saving initiative with the potential to improve public health outcomes significantly. As the UK continues its push towards becoming smoke-free, Varenicline offers a new hope for smokers looking to quit and contribute to the nation’s ambitious health goals.

Health

One in Four Teenagers Worldwide Does No Weekly Exercise, Study Finds

Published

on

Around 240 million adolescents worldwide did not take part in physical activity on any day of the week in 2025, with girls falling further behind boys, according to a major global study published in The Lancet Global Health.

The research found that teenagers averaged 2.7 active days per week, a figure that remained unchanged between 2010 and 2025. Only 14 per cent, or about one in seven adolescents, reported being active every day.

The study analysed 389 surveys covering 3.2 million young people aged 11 to 17 across 140 countries. The data represented approximately 59 per cent of the global adolescent population.

Researchers defined an active day as one on which a teenager completed at least 60 minutes of moderate-to-vigorous physical activity. This follows the recommendation of the World Health Organization (WHO), which counts activity at school, during travel and in leisure time.

The findings raise concerns about progress towards the WHO’s target of reducing the proportion of adolescents who fail to achieve 60 minutes of daily activity by 15 per cent between 2010 and 2030. The researchers found that no country or region was currently on track to meet the goal.

A clear gender gap emerged from the data. Boys averaged three active days per week in 2025, compared with 2.4 days for girls. The difference widened as girls grew older, suggesting that existing opportunities and programmes were not reaching them equally.

Geographical differences were also substantial. Adolescents in Central and Eastern Europe and Central Asia, East Asia and the Pacific, and high-income Western countries averaged around four active days each week. In these regions, between 6.9 and 7.7 per cent of teenagers reported no physical activity at all.

See also  Air Pollution Linked to Higher Cancer Risk and Death Rates, Report Warns

In contrast, young people in Latin America and the Caribbean, the Middle East and North Africa, Oceania, South and Southeast Asia, and sub-Saharan Africa averaged approximately two active days per week. The share reporting complete inactivity ranged from 22.7 to 33.1 per cent.

Finland, Canada and Serbia recorded the highest activity levels, with adolescents averaging between 4.5 and 4.8 active days weekly. Cambodia, Jordan and Madagascar were among the least active, averaging between 1.7 and 1.9 days.

The study’s authors linked these differences partly to structural conditions. Wealthier countries generally have more resources to support physical activity policies, provide public spaces and develop safe routes for walking and cycling.

The researchers said adolescence is an important period for establishing habits that influence health throughout adulthood. Regular exercise supports physical and mental wellbeing, but existing programmes are failing to reach large numbers of young people.

They called for stronger policies tailored to local conditions, with schools and neighbourhoods made more supportive of everyday activity. They also urged governments to address barriers affecting girls, including restrictive gender expectations, safety concerns and limited access to suitable sports and recreational activities.

Continue Reading

Health

Health Groups Urge WHO to Tighten Drinking Water Nitrate Limits Over Cancer Risks

Published

on

A coalition of 85 international health and environmental organisations has urged the World Health Organization (WHO) to revise its drinking water standards for nitrate, warning that exposure to levels below the existing limit may be associated with colorectal cancer and premature births.

In an open letter sent on Tuesday, the groups called on the United Nations health agency to include nitrate in its forthcoHealth Groups Urge WHO to Tighten Drinking Water Nitrate Limits Over Cancer Risks

ming review of drinking water guidelines. Signatories include Greenpeace International, the World Organization of Family Doctors (WONCA) and the European Environmental Bureau.

The organisations argue that the WHO’s current nitrate limit is based on standards established decades ago and does not adequately reflect more recent scientific evidence about the potential effects of long-term exposure.

Nitrates and nitrites are naturally occurring compounds found in soil, water and food. However, human activities, including the use of agricultural fertilisers, manure runoff and poorly maintained septic systems, can increase nitrate concentrations in water supplies.

The current WHO guideline sets the maximum acceptable nitrate concentration at 50 milligrams per litre (mg/L), equivalent to 11.3 mg/L when measured as nitrate-nitrogen. The standard dates back to 1958 and was originally designed to prevent methaemoglobinaemia, commonly known as blue-baby syndrome. The condition reduces the blood’s ability to carry oxygen and can be fatal in infants.

The organisations say the existing threshold does not account for epidemiological research linking prolonged exposure to lower nitrate concentrations with other health risks, particularly bowel cancer and adverse pregnancy outcomes.

See also  Diabetes Cases in the UK Reach Record High, Affecting One in Five Adults

“Studies now link nitrate in drinking water, at levels well below the current WHO limit, to bowel cancer and premature birth,” said Pratyush Kumar, chair of WONCA, in a joint statement.

Amanda Larsson, Greenpeace’s global project lead for agriculture, said access to safe drinking water should be treated as a basic guarantee rather than a privilege.

The coalition also cited a report commissioned by the Danish government last year, which concluded that the existing international standard was insufficient to protect public health. The expert panel recommended reducing the nitrate limit to 6.0 mg/L.

Denmark has committed to adopting the lower threshold, although it has not announced a timetable for implementation. The organisations said this creates a growing difference between international guidance and national drinking water policies.

Most governments use WHO recommendations as the basis for their own drinking water standards, making changes to the agency’s guidelines important for wider regulatory reform, the letter said.

The appeal was issued on World One Health Day, which highlights the links between human, animal and environmental health.

The signatories also called on governments to reduce pollution from intensive livestock farming and support producers in adopting more environmentally sustainable agricultural practices.

They said stronger protections against nitrate contamination were needed to safeguard drinking water supplies and reduce potential health risks, particularly for children and pregnant women.

Continue Reading

Health

Breast Cancer Screening Gaps Across Europe Leave Women Facing Unequal Access to Early Diagnosis

Published

on

A breast biopsy can bring days of uncertainty, fear and difficult memories, particularly for women with a family history of cancer. For Euronews reporter Monica Pinna, a week-long wait for test results became a personal experience of the emotional strain involved in investigating a possible diagnosis, as well as the inequalities affecting breast cancer screening and care across Europe.

Pinna had delayed a routine breast examination for around two years before attending an appointment in France. Her mammogram appeared normal, but an ultrasound revealed a suspicious area that required a biopsy. She underwent the procedure two days later and waited seven days for the results.

During that period, she recalled relatives who had survived breast cancer and others who had died from the disease. Although the uncertainty disrupted her work and daily life, the doctor eventually confirmed that there was no cancer.

Her experience highlighted a wider problem: access to early detection and timely diagnosis varies considerably between European countries.

When breast cancer is detected before it spreads, five-year survival rates approach 100%, compared with 38% for women diagnosed at an advanced stage, according to figures cited in the report. The European Commission has allocated around €80 million through its Europe’s Beating Cancer Plan to strengthen screening, but access remains uneven.

Differences in screening arrangements, appointment availability, out-of-pocket costs and public awareness all affect women’s chances of receiving an early diagnosis. Research by the European Union and the Organisation for Economic Co-operation and Development (OECD) has also identified social inequalities as a factor.

The time between screening and diagnosis varies across the continent. A study cited in the report found median waiting times ranging from eight days in Denmark to 32 days in Romania.

See also  UK Confirms 36 Possible Cases of Baby Formula Intoxication Amid Global Recalls

Maria Assunta, who lives in Sardinia, experienced a considerably longer process. At 46, a routine ultrasound identified a four-centimetre lump. She waited a month for a biopsy and another three weeks to receive her diagnosis. She is now in follow-up care, with examinations every six months, and describes the treatment she received as excellent.

Participation in organised screening programmes also remains inconsistent. In France, fewer than half of eligible women take part. Although screening rates increased in nine EU countries with available data compared with 2019, progress has stalled in many others.

Around 360,000 women in the EU are diagnosed with breast cancer each year, including approximately 61,000 in France. Estimates suggest that one in 11 women will develop the disease during their lifetime.

Access to psychological support is another concern. The OECD’s 2026 European Cancer Inequalities Report found that only 16 EU countries include psychological care in their cancer treatment pathways, alongside Norway and Iceland.

In Italy, a 2024 study of around 3,000 cancer patients found that only 20% had received psychological support. The Italian Federation of Voluntary Associations in Oncology estimates that specialised psycho-oncology services are available in only around 20% of hospitals.

Cancer survivors and medical volunteers have established initiatives to help address these gaps, offering activities such as yoga, Qigong and emotional support. However, provision remains limited and often depends on voluntary organisations.

Pinna’s experience ended with an all-clear, but she said it had changed her approach to screening. She hopes sharing her story will encourage women to attend regular examinations, while calling for faster diagnosis, wider access to treatment and psychological support across Europe.

Continue Reading

Trending